Digital Oral Presentation is now published on ECCO website: Here's the conclusion part :-
"IMP761 is the first LAG-3-specific product candidate that can inhibit antigen-specific T-cell–mediated immune responses in vitro and in vivo, for the treatment of auto-immune diseases".
March 6th 2019 - March 9th 2019
DOP Session 1 - Advances in IBD pathophysiology 2019
DOP07 IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases
M. Angin*1, C. Brignone1, F. Triebel1
1Immutep, Orsay, France
Big Year Ahead, page-48
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.3¢ |
Change
0.018(6.14%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.5¢ | 29.0¢ | $565.0K | 1.907M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 344870 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 237922 | 27 |
View Market Depth
| Last trade - 14.18pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
